Alpha‐Synuclein induces hyperphosphorylation of Tau in the MPTP model of Parkinsonism
The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Many neurodegenerative diseases associated with functional Tau dysregulation, including Alzheimer's disease (AD) and other tauopathies, also show α‐synuclein (α‐ Syn ) pathology, a protein associated with Parkinson's disease (PD) pathology. Here we show that treatment of primary mesencephalic neurons (48 h) or subchronic treatment of wild‐type (WT) mice with the Parkinsonism‐inducing neurotoxin MPP + /MPTP, results in selective dose‐dependent hyperphosphorylation of Tau at Ser396/404 (PHF‐1‐reactive Tau , p‐ Tau ), with no changes in pSer202 but with nonspecific increases in pSer262 levels. The presence of α ‐Syn was absolutely mandatory to observe MPP + /MPTP‐induced increases in p‐ Tau levels, since no alterations in p‐ Tau were seen in transfected cells not expressing α ‐Syn or in α ‐Syn ‐ / ‐ mice. MPP + /MPTP also induced a significant accumulation of α ‐Syn in both mesencephalic neurons and in WT mice striatum. MPTP/MPP + lead to differential alterations in p‐ Tau and α ‐Syn levels in a cytoskeleton‐bound, vs . a soluble, cytoskeleton‐free fraction, inducing their coimmunoprecipitation in the cytoskeleton‐free fraction and neuronal soma. Subchronic MPTP exposure increased sarkosyl‐insoluble p‐ Tau in striatum of WT but not α ‐Syn ‐ / ‐ mice. These studies describe a novel mechanism for MPTP neurotoxicity, namely a MPTP‐inducible, strictly α ‐Syn ‐dependent, increased formation of PHF‐1‐reactive Tau , suggesting convergent overlapping pathways in the genesis of clinically divergent diseases such as AD and PD. —Duka, T., Rusnak, M., Drolet, R. E., Duka, V., Wersinger, C., Goudreau, J. L., Sidhu, A. Alpha‐synuclein induces hyperphosphorylation of Tau in the MPTP model of Parkinsonism. FASEB J. 20, 2302–2312 (2006)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480 · cited 1×
“Our findings describe a novel linkage between MPTP neurotoxicity, -Syn accumulation, and increases in p-Tau levels, providing unique insights into the roles of these proteins in the genesis of not only MPTP-induced Parkinsonian syndromes but also of other neurodegenerative diseases associated with dysregulation of Tau…”
Backgroundα-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029
Bramblett, G. T., Goedert, M., Jakes, R., Merrick, S. E., Trojanowski, J. Q., & Lee, V. M. Y. (1993) · Neuron · doi:10.1016/0896-6273(93)90057-x · Cited by 903 · cited 1×
“The developmentally regulated Ser262 phosphorylation strongly inhibits Tau binding to MTs (24, 32 ) and is likely abnormally phosphorylated in AD PHFs (33).”
BackgroundInitiation and Synergistic Fibrillization of Tau and Alpha-Synuclein
Giasson, B. I., Forman, M. S., Higuchi, M., Golbe, L. I., Graves, C. L., Kotzbauer, P. T., Trojanowski, J. Q., & Lee, V. M.-Y. (2003) · Science · doi:10.1126/science.1082324 · Cited by 879 · cited 2×
“Despite their codeposition in certain neurological disorders and their enormous potential to either directly or indirectly interact with one another and/or modulate the molecular properties of each other, few studies have been conducted in this regard ( 21 , 22).”
BackgroundBiernat, J., Gustke, N., Drewes, G., Mandelkow, E., & Mandelkow, E. (1993) · Neuron · doi:10.1016/0896-6273(93)90279-z · Cited by 796
Tau phosphorylation in neuronal cell function and dysfunction
Johnson, G. V. W., & Stoothoff, W. H. (2004) · Journal of Cell Science · doi:10.1242/jcs.01558 · Cited by 624
Proline-directed and non-proline-directed phosphorylation of PHF-tau
Morishima-Kawashima, M., Hasegawa, M., Takio, K., Suzuki, M., Yoshida, H., Titani, K., & Ihara, Y. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.2.823 · Cited by 557
Monoclonal antibody PHF‐1 recognizes tau protein phosphorylated at serine residues 396 and 404
Otvos, L., Feiner, L., Lang, E., Szendrei, G. I., Goedert, M., & Lee, V. M. (1994) · Journal of Neuroscience Research · doi:10.1002/jnr.490390607 · Cited by 488 · cited 1×
“In vitro studies suggest that Ser396/404 hyperphosphorylation [PHF-1 antibody (Ab)-reactive site, referred to as p-Tau in this study] of Tau, characteristically found in PHFs of AD brain (34), as well as of the FTDP-17 mutated Tau found in frontotemporal dementia with parkinsonism linked to chromosome 17, may promote…”
Background
Cited by
Neuroinflammation as a common feature of neurodegenerative disorders
Guzman-Martinez, L., Maccioni, R. B., Andrade, V., Navarrete, L. P., Pastor, M. G., & Ramos-Escobar, N. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01008 · Cited by 702
Nguyen, P. H., Ramamoorthy, A., Sahoo, B. R., Zheng, J., Faller, P., Straub, J. E., Dominguez, L., Shea, J.-E., Dokholyan, N. V., De Simone, A., et al. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01122 · Cited by 678
Basic mechanisms of neurodegeneration: a critical update
Jellinger, K. A. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01010.x · Cited by 596
Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesis
John van Geest Centre for Brain Repair, D. O. C. N., Kouli, A., Torsney, K. M., Department of Medicine for the Elderly, C. U. H. N. F. T., Clinical Gerontology Unit, D. O. P. H. A. P. C., Kuan, W.-L., & John van Geest Centre for Brain Repair, D. O. C. N. (2018) · Parkinson’s Disease: Pathogenesis and Clinical Aspects · doi:10.15586/codonpublications.parkinsonsdisease.2018.ch1 · Cited by 507
Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts
Jellinger, K. A. (2012) · Movement Disorders · doi:10.1002/mds.23795 · Cited by 451
Baltazar, M. T., Dinis-Oliveira, R. J., de Lourdes Bastos, M., Tsatsakis, A. M., Duarte, J. A., & Carvalho, F. (2014) · Toxicology Letters · doi:10.1016/j.toxlet.2014.01.039 · Cited by 410
Alpha-synuclein and tau: teammates in neurodegeneration?
Moussaud, S., Jones, D. R., Moussaud-Lamodière, E. L., Delenclos, M., Ross, O. A., & McLean, P. J. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-43 · Cited by 287
Glycogen synthase kinase-3 beta (GSK-3β) signaling: Implications for Parkinson's disease
Golpich, M., Amini, E., Hemmati, F., Ibrahim, N. M., Rahmani, B., Mohamed, Z., Raymond, A. A., Dargahi, L., Ghasemi, R., & Ahmadiani, A. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.03.010 · Cited by 276
α‐Synuclein contributes to GSK‐3β‐catalyzed Tau phosphorylation in Parkinson's disease models
Duka, T., Duka, V., Joyce, J. N., & Sidhu, A. (2009) · The FASEB Journal · doi:10.1096/fj.08-120410 · Cited by 275
Self-citationRecent advances in our understanding of neurodegeneration
Jellinger, K. A. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0240-y · Cited by 274
“Induction of hyperphosphorylation of tau by aSyn in the 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine (MPTP) model of parkinsonism (Duka et al. 2006), and the co-location of phospho-tau and aSyn in both NFTs and LBs (Ishizawa et al. 2003; Shao et al. 2006) and the co-occurrence of abnormal deposition…”
BackgroundPrevalence and impact of vascular and Alzheimer pathologies in Lewy body disease
Jellinger, K. A., & Attems, J. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0347-5 · Cited by 268
Kumaran, R., & Cookson, M. R. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv236 · Cited by 86
“α-Synuclein has been reported to promote tau phosphorylation via GSK3β at S396 and other residues (110,111).”
BackgroundRoy, B., & Jackson, G. R. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu011 · Cited by 75
Metadata
- Authors
- Duka, T., Rusnak, M., Drolet, R. E., Duka, V., Wersinger, C., Goudreau, J. L., & Sidhu, A.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2006-11
- Volume
- 20
- Issue
- 13
- Pages
- 2302-2312
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W1985256275
- Cited by
- 112
- References
- 14
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.